The acquisition shows OpenAI extending its Rosalind life sciences models into operations for biopharma drug development teams, not just research tools.
We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development.
Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner.
Welcome @ashokaraj_ and team!
OpenAI · x.comPublished · added here
Original title: We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development.
